DelveInsight’s ‘Pre-Eclampsia Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Pre-Eclampsia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Pre-Eclampsia pipeline domain.
For Pre-Eclampsia emerging drugs, the Pre-Eclampsia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Pre-Eclampsia Pipeline Report
- Different Pre-Eclampsia pipeline therapies are in various stages of development, and their anticipated acceptance in the Pre-Eclampsia market would significantly increase market revenue.
- Leading Pre-Eclampsia companies developing novel drug candidates to improve the Pre-Eclampsia treatment landscape include Kyowa Kirin Co., Ltd, Pharming Group, Amag Pharmaceuticals, MirZyme, Evergreen Therapeutics, Dilafor, and others.
- Promising Pre-Eclampsia pipeline therapies in various stages of development include KW3357, rhC1INH protein replacement therapy, siRNA therapy, C103, GMA312, Tafoxiparin, EG-101, and others.
Request a sample and discover the recent breakthroughs happening Pre-Eclampsia pipeline landscape in @ Pre-Eclampsia Pipeline Report
Pre-Eclampsia is a pregnancy complication marked by high blood pressure and signs of organ damage, most commonly the liver and kidneys. Pre-Eclampsia is a pregnancy condition characterized by hypertension (high blood pressure) and proteinuria (the presence of protein in your urine). It usually appears during the third trimester. The condition affects between 5% and 8% of pregnancies and has serious health consequences for mothers and babies. There is no single cause, but genetic factors and blood vessel problems are two possibilities. Pre-Eclampsia, if left untreated, can cause serious – even fatal – complications for both mother and baby.
Pre-Eclampsia Pipeline Analysis: Drug Profile
Tafoxiparin, a proprietary heparan sulfate mimetic, has been shown in preclinical and clinical data to supplement and fulfill the role of heparan sulfate, which is required for optimal oxytocin effectiveness. Tafoxiparin’s mechanism of action has been supported by preclinical experiments and clinical studies when used in conjunction with oxytocin in current clinical practice. Tafoxiparin can improve uterine contractions and may promote cervical softening, potentially lowering the incidence of protracted labor and its associated complications. The drug is currently in Phase III development for the treatment of preeclampsia.
KW3357: Kyowa Kirin Co., Ltd.
KW-3357 is an antithrombin (AT) drug developed using recombinant DNA and sugar-chain control technology. It is a recombinant AT preparation with the same amino acid sequence and sugar chain structure as human natural AT. AT inhibits blood coagulation by forming a complex with the proteolytic enzyme’s coagulation factor. Since July 2015, KW-3357 has been approved in Japan for treating thrombophilia due to congenital AT deficiency (CAD) and disseminated intravascular coagulation (DIC) and is marketed under the brand name ACOALAN. Kyowan Kirin Co., Ltd is currently developing KW3357 in collaboration with Japan Blood Products Organization for Preeclampsia.
Pre-Eclampsia Pipeline Therapies and Key Companies
- KW3357: Kyowa Kirin Co., Ltd.
- rhC1INH protein replacement therapy: Pharming Group
- Tafoxiparin: Dilafor
- EG-101: Evergreen Therapeutics
- Preeclampsia Research Project: MirZyme
- siRNA therapy: Comanche Biopharma
- C 103: Vicore Pharma
- GMA 312: Gmax Biopharm
Learn more about the Pre-Eclampsia emerging pipeline therapies @Pre-Eclampsia Clinical Trials
Pre-Eclampsia Pipeline Therapeutics Assessment
- By Product Type
- Combination Therapy
- By Stage
- Phase I
- Phase II
- Phase III
- By Route of Administration
- By Molecule Type
- Replacement Therapy
- Physiological Saline
Scope of the Pre-Eclampsia Pipeline Report
- Coverage: Global
- Key Pre-Eclampsia Companies: Kyowa Kirin Co., Ltd, Pharming Group (AMS: PHARM), Amag Pharmaceuticals, MirZyme, Evergreen Therapeutics, Dilafor, and others.
- Key Pre-Eclampsia Pipeline Therapies: KW3357, rhC1INH protein replacement therapy, siRNA therapy, C103, GMA312, Tafoxiparin, EG-101, and others.
Dive deep into rich insights for Pre-Eclampsia emerging therapies and assessment; visit @ Pre-Eclampsia Emerging Therapies
Table of Contents
|2.||Pre-Eclampsia Executive Summary|
|4.||Pre-Eclampsia Pipeline Therapeutics|
|5.||Pre-Eclampsia Pipeline: Late Stage Products (Phase III)|
|6.||Pre-Eclampsia Pipeline: Mid Stage Products (Phase II)|
|7.||Pre-Eclampsia Pipeline: Early Stage Products (Phase I/II)|
|8.||Pre-Eclampsia Pipeline: Preclinical Stage Products|
|9.||Pre-Eclampsia Pipeline: Discovery Stage Products|
|10.||Pre-Eclampsia Pipeline Therapeutic Assessment|
|11.||Pre-Eclampsia Pipeline: Inactive Products|
|12.||Collaborations Assessment- Licensing / Partnering / Funding|
|14.||Market Drivers and Barriers|
For further information on the Pre-Eclampsia current pipeline therapeutics, reach out @ Pre-Eclampsia Therapeutics Assessment
Pre-Eclampsia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gene therapy In Pre-Eclampsia companies, including Pharming Group, Amag Pharmaceuticals, MirZyme, Evergreen Therapeutics, Dilafor, among others.
Pre-Eclampsia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the Pre-Eclampsia epidemiology trends.
Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary hypertension companies, including Cumberland Pharmaceuticals, AstraZeneca, Aerovate Therapeutics, Celon Pharma, Camurus, ATXA Therapeutics, among others.
Pulmonary Hypertension Pipeline
Pulmonary Hypertension Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, among others.
Pulmonary Arterial Hypertension Pipeline
Pulmonary Arterial Hypertension Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Merck, Complexa, Acceleron Pharma, Ribomic, among others.
Other Trending Reports
Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn